Commitments and Contingencies (Details Narrative) |
1 Months Ended | 3 Months Ended | 12 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 26, 2019
USD ($)
|
Sep. 13, 2018
USD ($)
|
Sep. 13, 2018
EUR (€)
|
Aug. 12, 2016
USD ($)
|
May 05, 2016
USD ($)
|
May 05, 2016
AUD ($)
|
May 31, 2017
USD ($)
|
Jun. 30, 2012 |
Sep. 30, 2020
USD ($)
shares
|
Sep. 30, 2020
EUR (€)
shares
|
Jun. 30, 2019
USD ($)
|
Jun. 30, 2019
EUR (€)
|
Jun. 30, 2018
USD ($)
|
Jun. 30, 2017
USD ($)
|
Jun. 30, 2020
USD ($)
|
Jul. 02, 2019
USD ($)
|
|
| Penalty amount | $ 30,000 | |||||||||||||||
| Right-of-use assets | 15,792 | $ 21,682 | ||||||||||||||
| Total lease liabilities | 19,957 | |||||||||||||||
| Payment for services | 24,660 | $ 36,117 | ||||||||||||||
| Revenue [Member] | ||||||||||||||||
| Royalties percentage | 2.00% | 2.00% | ||||||||||||||
| Accounting Standards Update 2016-02 [Member] | ||||||||||||||||
| Right-of-use assets | $ 48,662 | |||||||||||||||
| Total lease liabilities | $ 48,662 | |||||||||||||||
| Incremental borrowing rate | 6.00% | |||||||||||||||
| Euros [Member] | ||||||||||||||||
| Payment for services | € | € 21,050 | € 31,754 | ||||||||||||||
| Royalty Agreement Terms [Member] | ||||||||||||||||
| Operating leases income statement revenue percentage | 2.00% | |||||||||||||||
| License Agreement Terms [Member] | ||||||||||||||||
| Operating leases income statement revenue percentage | 5.00% | |||||||||||||||
| New Five-Year Operating Lease Agreement [Member] | ||||||||||||||||
| Operating lease term | 5 years | 5 years | ||||||||||||||
| Payments for rent | $ 2,431 | |||||||||||||||
| Lease description | The initial rental amount was $3,000 AUD subject to a 3% yearly escalation. | The initial rental amount was $3,000 AUD subject to a 3% yearly escalation. | ||||||||||||||
| New Five-Year Operating Lease Agreement [Member] | AUD Currency [Member] | ||||||||||||||||
| Payments for rent | $ 3,606 | |||||||||||||||
| Manufacturing Services Agreement [Member] | Minimum [Member] | ||||||||||||||||
| Anticipated milestone payment | $ 2,500,000 | |||||||||||||||
| Manufacturing Services Agreement [Member] | Maximum [Member] | ||||||||||||||||
| Anticipated milestone payment | $ 5,000,000 | |||||||||||||||
| Amatsigroup Agreement [Member] | ||||||||||||||||
| Payments description | The Company anticipates that its payments to Amatsigroup under the MSA will range between $2.5 million and $5.0 million over three years, when the finished drug product is manufactured and released for clinical trials. The Company has spent a total of $1,689,146 of costs to date under this contract of which $49,854 was expensed in fiscal 2019, $701,973 in fiscal 2018 and $937,319 in fiscal 2017. The MSA expired in 2019 and may be extended by mutual agreement in writing with a possible extension currently under consideration. | |||||||||||||||
| Contract cost | 1,689,146 | $ 49,854 | $ 701,973 | $ 937,319 | ||||||||||||
| One-Year Collaboration Agreement [Member] | ||||||||||||||||
| Payment for services | $ 59,508 | |||||||||||||||
| One-Year Collaboration Agreement [Member] | Euros [Member] | ||||||||||||||||
| Payment for services | € | € 52,000 | |||||||||||||||
| Two-Year Collaboration Agreement [Member] | ||||||||||||||||
| Payment for services | $ 45,775 | |||||||||||||||
| Two-Year Collaboration Agreement [Member] | Euros [Member] | ||||||||||||||||
| Payment for services | € | € 40,000 | |||||||||||||||
| From 2012 through the 2014 [Member] | ||||||||||||||||
| Penalty amount | 10,000 | |||||||||||||||
| Regal Consulting, LLC [Member] | ||||||||||||||||
| Loss contingency amount | $ 400,000 | |||||||||||||||
| Number of shares issued for services | shares | 60,000 | 60,000 | ||||||||||||||
| Regal Consulting, LLC [Member] | 2017 Note [Member] | ||||||||||||||||
| Convertible note | $ 106,500 | |||||||||||||||
| Penalty amount | $ 100,000 | |||||||||||||||
| Foley Shechter [Member] | ||||||||||||||||
| Legal fees | $ 151,032 | |||||||||||||||
| Potential liability reduction | $ 51,032 | |||||||||||||||